FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature

NARİN, Yavuz; AKSOY, Kader Uğur; Keleş, Erol; DAĞLI, Adile Ferda; Koç, Zehra Pınar

FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature

Zehra Pınar KOÇ, (Department ol Nuclear Medicine, Mersin University Faculty of Medicine, Mersin)

Kader Uğur AKSOY, (Department ol Nuclear Medicine, Mersin University Faculty of Medicine, Mersin)

Erol KELEŞ, (Department ol Nuclear Medicine, Mersin University Faculty of Medicine, Mersin)

Adile Ferda DAĞLI, (Department ol Nuclear Medicine, Mersin University Faculty of Medicine, Mersin)

Yavuz NARİN (Department ol Nuclear Medicine, Mersin University Faculty of Medicine, Mersin)

Türkiye Klinikleri Tıp Bilimleri Dergisi

0 0

Yıl: 2017 Cilt: 37 Sayı: 1 Sayfa Aralığı: 43 - 47 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature

Öz:

Tümör göstergeleri medüller tiroid karsinomu hastalarında diğer ultrasonografi gibi görün-- tüleme metodlarına ek olarak güvenilir olduğu kabul edilerek kullanılmaktadır. Bazı durumlarda bu hastalarda takipte toraks ve tüm vücut görüntüleme de gerekli olabilir. Kalsitonin ve karsinoem-- briyonik antijen birlikte medüller tiroid karsinomu takibinde güvenilir olarak kullanılır ve yüksel-- meleri nüksü gösterir ve rekürrens alanı F--18 FDG PET/BT gibi tetkiklerle tanımlanabilir ki bizim hastamizda bu negatif idi. Biz bu vaka ile nadiren görülen düşük kalsitonin düzeyine karşılık yük-- sek karsinoembriyonik antijen yüksekliği ile tanı alan yanlış CEA pozitifliğini raporluyor ve me-- düller tiroid karsinomunda tanısal metodlar ile tümör göstergelerinin yerini tartışıyoruz.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

FDG PET/BT Negatif Yükselmiş CEA Değerleri Olan Medüller Tiroid Karsinomu Hastası; Olgu Sunumu ve Literatür Derlemesi

Öz:

The tumor markers are considered reliable in follow up of Medullary Thyroid carci— noma (MTC) as an adjunct with other imaging methods like ultrasonography. In some circum— stances imaging of thorax or whole body imaging may be necessary in these patients in the follow up. Calcitonin levels in combination with carcinoembryonic antigen is markers that we use in the follow up of MTC patients which elevation indicates recurrence and the recurrence cite may be de— scribed by means of Fluorine—18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (F—18 FDG PET/CT) imaging which was negative in our case. In this case we report patient with exceptionally high carcinoembryonic antigen (CEA) and low calcitonin level in one month postoperative follow up who was diagnosed as having false positive CEA elevation and dis— cuss the diagnostic methods and tumor markers in detection of the Medullary Thyroid carcinoma.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık

1. Göksu SS, Göksu UA, Gündüz S, Coskun HS. Rising CEA levels in a patient with colon carcinoma: metachronous medullary thyroid cancer. Int J Biol Markers 2014;29(2):e184- 6.
2. Kauhanen S, Schalin-Jäntti C, Seppänen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med 2011;52(12):1855-63.
3. Verbeek HH, Plukker JT, Koopmans KP, de Groot JW, Hofstra RM, Muller Kobold AC, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 2012;53(12):1863-71.
4. Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a metaanalysis. Endocrine 2012;42(3):535-45.
5. Rufini V, Castaldi P, Treglia G, Perotti G, Gross MD, Al-Nahhas A, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 2008;62(3):139-46.
6. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25(1):79-83.
7. Bombardieri E, Maccauro M, Castellani MR, Chiti A, Procopio G, Bajetta E, et al. [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?]. Minerva Endocrinol 2001;26(4):197-213.
8. Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 2000;25(2):273-82.
9. Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27(5):490-6.
10. Grünwald F, Briele B, Biersack HJ. Non-131Iscintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET? Q J Nucl Med 1999;43(3):195- 206.
11. Salaun PY, Campion L, Bournaud C, FaivreChauvet A, Vuillez JP, Taieb D, et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med 2012;53(8):1185-92.
12. Mucha SA, Kunert-Radek J, Pomorski L. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases. Endokrynol Pol 2006;57(4):452- 5.
13. Adams S, Baum RP, Hertel A, SchummDräger PM, Usadel KH, Hör G. Metabolic (PET) and receptor (SPET) imaging of welland less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 1998;19(7):641-7.
14. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-Omethyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007;34(10):1604- 9.
15. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999;229(6):880-7.
16. Fialkowski EA, Moley JF. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 2006;15(8):737-47.
17. Skoura E, Datseris IE, Rondogianni P, Tsagarakis S, Tzanela M, Skilakaki M, et al. Correlation between Calcitonin Levels and [(18)F]FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid Cancer. ISRN Endocrinol 2012;2012:375231.
18. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 2001;8(2):135-47.
19. Bogsrud TV, Hay ID, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, et al. Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nucl Med Commun 2011;32(4):245-51.
20. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88(5):2070-5.
21. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28(11):1671-6.
22. Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007;48(4):501-7.
23. Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a metaanalysis. Endocrine 2012;42(3):535-45.
24. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al; American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19(3):565-612.
25. Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat A, et al; French Medullary Study Group (GETC). Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2001;55(3): 403-9.
26. Modigliani E, Cohen R, Campos JM, ConteDevolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’é- tude des tumeurs à calcitonin. Clin Endocrinol (Oxf) 1998;48(3):265-73.
27. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88(5):1139-48.
28. Laure Giraudet A, Al Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008;158(2):239-46.
29. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008;49(4):524-31.
30. Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma. Nucl Med Commun 2011;32(12):1162-8.
31. de Groot JW, Kema IP, Breukelman H, van der Veer E, Wiggers T, Plukker JT, et al. Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid 2006;16(11):1163-70.
32. Laure Giraudet A, Al Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008;158(2):239-46.
33. Litvak A, Cercek A, Segal N, Reidy-Lagunes D, Stadler ZK, Yaeger RD, et al. False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J Natl Compr Canc Netw 2014;12(6):907-13.
34. Sousa RG, Nunes A, Meira T, Carreira O, Pires AM, Freitas J. Colonoscopy and carcinoembryonic antigen variations. Arq Gastroenterol 2014;51(1):69-72.
35. Hampton R, Walker M, Marshall J, Juhl H. Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells. Oncogene 2002;21(51):7817-23.
36. Bertolini L, Meschi M, Detrenis S, Maggiore U, Savazzi G. [Serum concentration of some tumor markers in renal failure]. Recenti Prog Med 2005;96(5):221-5.
37. Asad-Ur-Rahman F, Saif MW. Elevated Level of Serum Carcinoembryonic Antigen (CEA) and Search for a Malignancy: A Case Report. Cureus 2016;8(6):e648.

APA	Koç Z, AKSOY K, Keleş E, DAĞLI A, NARİN Y (2017). FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. , 43 - 47.
Chicago	Koç Zehra Pınar,AKSOY Kader Uğur,Keleş Erol,DAĞLI Adile Ferda,NARİN Yavuz FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. (2017): 43 - 47.
MLA	Koç Zehra Pınar,AKSOY Kader Uğur,Keleş Erol,DAĞLI Adile Ferda,NARİN Yavuz FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. , 2017, ss.43 - 47.
AMA	Koç Z,AKSOY K,Keleş E,DAĞLI A,NARİN Y FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. . 2017; 43 - 47.
Vancouver	Koç Z,AKSOY K,Keleş E,DAĞLI A,NARİN Y FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. . 2017; 43 - 47.
IEEE	Koç Z,AKSOY K,Keleş E,DAĞLI A,NARİN Y "FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature." , ss.43 - 47, 2017.
ISNAD	Koç, Zehra Pınar vd. "FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature". (2017), 43-47.

APA	Koç Z, AKSOY K, Keleş E, DAĞLI A, NARİN Y (2017). FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. Türkiye Klinikleri Tıp Bilimleri Dergisi, 37(1), 43 - 47.
Chicago	Koç Zehra Pınar,AKSOY Kader Uğur,Keleş Erol,DAĞLI Adile Ferda,NARİN Yavuz FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. Türkiye Klinikleri Tıp Bilimleri Dergisi 37, no.1 (2017): 43 - 47.
MLA	Koç Zehra Pınar,AKSOY Kader Uğur,Keleş Erol,DAĞLI Adile Ferda,NARİN Yavuz FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. Türkiye Klinikleri Tıp Bilimleri Dergisi, vol.37, no.1, 2017, ss.43 - 47.
AMA	Koç Z,AKSOY K,Keleş E,DAĞLI A,NARİN Y FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2017; 37(1): 43 - 47.
Vancouver	Koç Z,AKSOY K,Keleş E,DAĞLI A,NARİN Y FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2017; 37(1): 43 - 47.
IEEE	Koç Z,AKSOY K,Keleş E,DAĞLI A,NARİN Y "FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature." Türkiye Klinikleri Tıp Bilimleri Dergisi, 37, ss.43 - 47, 2017.
ISNAD	Koç, Zehra Pınar vd. "FDG PET/CT Negative Medullary Thyroid Carcinoma Patient with Elevated CEA Level: Case Report and Review of Literature". Türkiye Klinikleri Tıp Bilimleri Dergisi 37/1 (2017), 43-47.